NVO - Novo Nordisk A/S
| Previous Close | 43.57 |
| Open | 43.61 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1300 |
| Day's Range | 43.50 - 44.32 |
| 52 Week Range | 41.23 - 58.37 |
| Volume | 1,101,936 |
| Avg. Volume | 1,540,516 |
| Market Cap | 105.781B |
| Beta (3Y Monthly) | 1.14 |
| PE Ratio (TTM) | 17.94 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.27 (2.82%) |
| Ex-Dividend Date | 2018-08-17 |
| 1y Target Est | 47.20 |
- Insider Monkey•3 days ago
Novo Nordisk A/S (NVO): Hedge Fund Sentiment Going Nowhere
The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings discloses the funds’ positions on June […]
- Motley Fool•8 days ago
Novo Nordisk Continues Its Balancing Act
Growth on one hand, but declines on the other.
- Zacks•15 days ago
Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.
- The Wall Street Journal•16 days ago
[$$] Danish Insulin Maker Novo Nordisk Cuts Jobs, Shifts R&D Spending
A/S is cutting costs and reallocating research and development spending as it faces price pressures in the U.S., its biggest market. Four hundred jobs will be eliminated in the company’s research and development unit. Most of the savings in the R&D department will be reinvested in artificial intelligence, cloud services and automation technologies, Mr. Knudsen said.
Motley Fool•16 days agoNovo Nordisk (NVO) Q3 2018 Earnings Conference Call Transcript
NVO earnings call for the period ending September 30, 2018.
Reuters•16 days agoUpbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure
Novo Nordisk (NOVOb.CO), the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's (LLY.N) Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.
- Reuters•16 days ago
Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure
Novo Nordisk, the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.
- Associated Press•16 days ago
Novo Nordisk: 3Q Earnings Snapshot
On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 58 cents. The drugmaker posted revenue of $4.31 billion in the period. Novo Nordisk shares have fallen 19 percent since ...
- CNBC•16 days ago
Novo Nordisk earnings miss expectations amid currency headwinds
Denmark's Novo Nordisk reported weaker-than-expected earnings on Thursday, citing currency headwinds.
- Benzinga•16 days ago
Q3 Earnings Preview For Novo Nordisk
Novo Nordisk A/S (NYSE: NVO ) releases its next round of earnings this Thursday, Nov. 1. Here's Benzinga's essential guide to Novo Nordisk's Q3 earnings report. Earnings and Revenue Wall Street expects ...
- GlobeNewswire•22 days ago
Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence
NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Market Realist•24 days ago
What Analysts Recommend for Novartis after Q3 Earnings
Wall Street analysts estimate that Novartis will report revenues of $13.4 billion during the fourth quarter of 2018, a 4.0% increase in year-over-year revenues as compared to $12.9 billion during the fourth quarter of 2017. The earnings-per-share is estimated at $1.29 during the fourth quarter of 2018. Analysts estimate the net income margin to increase to 22.1% during the fourth quarter of 2018 as compared to 21.8% during the fourth quarter of 2017.
- Market Realist•25 days ago
How Novartis’s Alcon Performed in Third Quarter
Alcon, the eye care business of Novartis AG (NVS), includes surgical products and vision care products. Alcon reported revenues of ~$1.76 billion during the third quarter of 2018, a 3% increase in year-over-year (or YoY) revenues as compared to ~$1.71 billion in the third quarter of 2017. The growth was driven by a 5% growth in operating revenues, offset by a 2% negative impact of foreign exchange.
GuruFocus.com•25 days ago5 Undervalued Companies With Predictable Businesses
According to the GuruFocus All-in-One Screener, the following companies have high business predictability ratings and a wide margin of safety. Warning! GuruFocus has detected 3 Warning Signs with WLK. The company has a 3.5-star out of five business predictability rating and, according to the discounted cash flow calculator, a 54% margin of safety at $74 per share.
- Market Realist•25 days ago
How Novartis’s Innovative Medicines Business Performed in Q3
Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.
- Zacks•last month
Novo Nordisk (NVO) Faces Pricing Pressure and Competition
Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.
- Reuters•last month
Minnesota accuses insulin makers of deceptive drug pricing
In a lawsuit filed in federal court in Trenton, New Jersey, Minnesota Attorney General Lori Swanson took aim at the companies after the list price for some insulin products more than tripled since 2002. The lawsuit alleged that companies fraudulently set artificially high list price for their products while offering rebates to pharmacy benefit managers (PBMs) in exchange for them covering the drug on behalf of health plans.
- Reuters•last month
Minnesota accuses insulin makers of deceptive drug pricing
Minnesota's attorney general on Tuesday filed a lawsuit accusing drug manufacturers Sanofi SA, Novo Nordisk and Eli Lilly and Co of deceptively raising prices for insulin. In a lawsuit filed in federal court in Trenton, New Jersey, Minnesota Attorney General Lori Swanson took aim at the companies after the list price for some insulin products more than tripled since 2002.
GuruFocus.com•last month6 Companies Growing Their Book Value
Brookfield Asset Management tops the list
Reuters•last monthNovo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.
- Zacks•last month
PFE or NVO: Which Is the Better Value Stock Right Now?
PFE vs. NVO: Which Stock Is the Better Value Option?
- Reuters•last month
Novo Nordisk could close biopharma acquisition this year - CEO
COPENHAGEN (Reuters) - Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday. "It is not always easy ...
Market Realist•last monthHealthcare Stocks in the Red amid Broader Market Sell-Off
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
- Market Realist•last month
How Novartis’s Businesses Have Been Performing
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
- Benzinga•last month
The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...
